A hardly soluble beverage product, comprising: a container comprising a main body that contains a content and that has a container mouth as an outlet of the content, and a cap that is mounted on the container mouth to close the main body. An internal volume of the container is set to a total of: a volume corresponding to a volume of the powder material contained in the container; a volume corresponding to an amount of the liquid determined in accordance with an amount of the powder material to be mixed or dissolved with the liquid; and a volume as an extra space to cause turbulence of the powder material and the liquid.

An object of the present invention is to provide a technique for preventing infection of pathogenic viruses, which cause infectious diseases in animals or humans. A nutritional composition containing lactoferrin and/or lactoferrin hydrolysate, and human milk oligosaccharide is provided. One or more human milk oligosaccharides are preferably 2′-fucosyllactose, 3-fucosyllactose, 3′-sialyllactose, and 6′-sialyllactose. The nutritional compositions of the present invention can be used for preventing infection, especially for preventing viral infection.

Featured are a foodstuff containing an inter-alpha inhibitor protein (lαlp) (e.g., lαl, Pαl, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof), methods of preparing a food-stuff containing an lαlp, and methods of treating and/or reducing the likelihood of developing a disease or condition (e.g., a disease or condition characterized by inflammation and/or low levels of an lαlp) in a subject in need thereof by administering a composition or a foodstuff containing an lαlp. Also featured are methods of purifying an lλlp (e.g., lαl, Pαl, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof) from milk.

Food compositions comprising a milk ingredient and oats are described. Food compositions described provide a convenient alternative to overnight oats. Food products containing food compositions that include a milk ingredient and oats, as well as methods of making and using such food compositions and food products are also described.

The present invention relates to bovine milk fat comprising, based on total fatty acid content, 8.9-29.0 wt % linoleic acid (C18:2 cis, 9,12), 0.9-2.4 wt % alpha-linolenic acid (C18:3 cis 9,12,15), and 3-5 wt % butyric acid (C4:0). The present invention further relates to a bovine milk comprising said milk fat and to a method for producing said milk by feeding a lactating bovine mammal with a rumen-protected linoleic acid source and a rumen-protected alpha-linolenic acid source, followed by milking the lactating bovine animal.

The invention concerns a sweetened strained fermented dairy product comprising a dairy material, at least one steviol glycoside, at least one additive selected from a polysaccharide of fructose units and a salt. The product may further comprise a lactase enzyme.

Provided herein is a composition that includes choline or choline salt and omega-3 fatty acid for nutritionally enhancing a food product, as well as the resultant food products. The food product when nutritionally enhanced with the composition has an acceptable taste or acceptable odor or the food product has a peroxide value of less than 50 mEq. Methods of preparing the composition and food products are also are provided. As seen in the accompanying figure the discoveries outlined herein have resulted in an unprecedented level of organoleptic stability over time, with no significant change to key sensory parameters typically seen in products that contain high levels of choline and omega-3 fatty acids.

Provided are compositions and methods for treating, ameliorating and preventing various infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor, where exemplary compositions are products of manufacture, a food, a drink, a nutraceutical, a dietary supplement, a formulation, a pharmaceutical or a pharmaceutical preparation comprising at least one or several of: a plurality of isolated, or substantially purified bacteriophages or prophages, or bacteriophage subunits, a milk, a milk product, milk lipid, milk fat globule (MFG) macromolecule, a milk mucin, a milk glycolipid, a milk free glycan, a milk mucin-like glycoprotein, a milk protein, a milk sugar or lactose, a milk fat or butterfat, a milk vitamin. In alternative embodiment, provided are compositions and methods for treating, preventing or ameliorating an infection, for example, an infection in the gastrointestinal tract, or bowel.

Provided are compositions and methods for treating, ameliorating and preventing various infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor, where exemplary compositions are products of manufacture, a food, a drink, a nutraceutical, a dietary supplement, a formulation, a pharmaceutical or a pharmaceutical preparation comprising at least one or several of: a plurality of isolated, or substantially purified bacteriophages or prophages, or bacteriophage subunits, a milk, a milk product, milk lipid, milk fat globule (MFG) macromolecule, a milk mucin, a milk glycolipid, a milk free glycan, a milk mucin-like glycoprotein, a milk protein, a milk sugar or lactose, a milk fat or butterfat, a milk vitamin. In alternative embodiment, provided are compositions and methods for treating, preventing or ameliorating an infection, for example, an infection in the gastrointestinal tract, or bowel.

The present invention relates to novel Weissella hellenica WiKim0103 isolated from Kimchi and a composition comprising the same or its use. The present invention provides a method for prevention, improvement and treatment of inflammation, obesity or fatty liver disease of a subject by administering the novel Weissella hellenica WiKim0103 isolated from Kimchi or a composition comprising thereof. The Weissella hellenica WiKim0103 according to the present invention shows an inhibitory effect for fatty liver production by inhibiting fat accumulation in liver cells and reducing expression of fatty liver-related genes, and thus it may be variously utilized for uses in prevention, improvement and treatment of inflammation, obesity or fatty liver disease.